

PHARMACEUTICAL 2021

NANOVIRICIDES INC. Rank 115 of 402







PHARMACEUTICAL 2021

NANOVIRICIDES INC. Rank 115 of 402

The relative strengths and weaknesses of NANOVIRICIDES INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NANOVIRICIDES INC. compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 83% points. The greatest weakness of NANOVIRICIDES INC. is the variable Net Income, reducing the Economic Capital Ratio by 41% points.

The company's Economic Capital Ratio, given in the ranking table, is 184%, being 137% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	13,986
Cost of Goods Sold	0
Intangible Assets	358
Liabilities, Current	2,156
Liabilities, Non-Current	0
Other Assets	26
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-5,450
Other Revenues	0
Property and Equipment	9,544
Research and Development	4,696
Selling, General and Administrative Expense	3,301

Output Variable	Value in 1000 USD
Assets	23,914
Liabilities	2,156
Expenses	7,996
Revenues	0
Stockholders Equity	21,758
Net Income	-13,447
Comprehensive Net Income	-13,447
Economic Capital Ratio	184%

